The Predictive Value of Tenascin‐C, Neopterin and Pro‐Inflammatory Cytokines (IFN‐γ, TNF‐α, IL‐6) in Alcohol Use Disorder Treatment Response
Addiction Biology · 2026-08 · 31 (8)
DOI: 10.1111/adb.70181 ↗At a glance
Beobachtungsstudie in Addiction Biology, published online on 2026-07-23. Written by Guleser Akpinar and 6 co-authors. Institution: Department of Emergency Medicine, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey. Major MEDLINE topics: Neopterin, Tenascin, Interferon-gamma, Interleukin-6. 28 references. The full text is freely available (open access, CC BY 4.0).
Topics: Sucht und Abhängigkeit
Abstract (original language)
The underlying neurobiological mechanisms of chronic alcohol consumption, particularly neuroinflammation and immune system dysregulation, have been extensively studied in recent years. In this process, the identification of objective biomarkers that can predict treatment response and enable personalized medicine approaches is of critical importance. This study aimed to evaluate the potential predictive value of tenascin‐C (TNC), an extracellular matrix protein, neopterin, a marker of cellular immune activation and pro‐inflammatory cytokines interferon‐gamma (IFN‐γ), tumour necrosis factor‐alpha (TNF‐α) and interleukin‐6 (IL‐6), during the treatment process for alcohol use disorder (AUD). This prospective observational cohort study included 30 patients admitted to an AUD treatment centre and 31 healthy controls. Serum TNC, IL‐6, TNF‐α and IFN‐γ levels were measured using the ELISA method. Clinical outcomes were assessed using the SCL‐90‐R and API‐K scales. Serum samples were collected from patients at admission and on the 7th day of detoxification treatment. Baseline serum TNC levels in the alcohol group (131.78 ± 50.92 ng/mL) were significantly higher than in the healthy control group (63.92 ± 23.85 ng/mL). In the alcohol group, TNC ( p = 0.007) and AST ( p = 0.025) levels decreased significantly, while vitamin B12 ( p = 0.002) and platelet count ( p = 0.012) increased. No significant difference was observed in neopterin and cytokine levels (TNF‐α, IL‐6 and IFN‐γ) between baseline and follow‐up measurements. Clinical assessments showed significant improvements in depression ( p = 0.041), anxiety ( p = 0.014) and total symptom scores ( p = 0.026) on the SCL‐90‐R scale. ROC analysis showed that a reduction of 28.22% or more in TNC predicted clinical improvement with an overall accuracy rate of 73.33%.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Emergency Medicine, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey.
- Department of Medical Biochemistry, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey.
- Department of Child and Adolescent Mental Health and Disorders, Bakirkoy Prof. Dr. Mazhar Osman Mental Health and Neurological Diseases Training and Research Hospital, Istanbul, Turkey.
- Department of Emergency Medicine, Faculty of Medicine, Biruni University, Istanbul, Turkey.
- Department of Neurology, Istanbul Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey.
ORCID profiles: Guleser Akpinar, Enes Faruk Altunkiliç, Alp Batuhan Ozturk
Cite
APA
Akpinar, G., Sener, G., Altunkiliç, E. F., Yazgec, E., Ozturk, A. B., Basan, N. M., & Ozsemerci, H. A. (2026). The Predictive Value of Tenascin‐C, Neopterin and Pro‐Inflammatory Cytokines (IFN‐γ, TNF‐α, IL‐6) in Alcohol Use Disorder Treatment Response. Addiction Biology, 31(8). https://doi.org/10.1111/adb.70181
Vancouver
Akpinar G, Sener G, Altunkiliç EF, Yazgec E, Ozturk AB, Basan NM, et al. The Predictive Value of Tenascin‐C, Neopterin and Pro‐Inflammatory Cytokines (IFN‐γ, TNF‐α, IL‐6) in Alcohol Use Disorder Treatment Response. Addiction Biology. 2026;31(8). doi:10.1111/adb.70181
BibTeX
@article{Akpinar2026,
author = {Akpinar, Guleser and Sener, Gulsen and Altunkiliç, Enes Faruk and Yazgec, Emre and Ozturk, Alp Batuhan and Basan, Nuri Mehmet and Ozsemerci, Huseyin Aycan},
title = {The Predictive Value of Tenascin‐C, Neopterin and Pro‐Inflammatory Cytokines (IFN‐γ, TNF‐α, IL‐6) in Alcohol Use Disorder Treatment Response},
journal = {Addiction Biology},
year = {2026},
volume = {31},
number = {8},
doi = {10.1111/adb.70181}
}
EUVIMED